Matt Miksic
Stock Analyst at Barclays
(0.73)
# 1827
Out of 5,240 analysts
245
Total ratings
57.73%
Success rate
7.88%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
InMode | Maintains: Overweight | 27 26 | 16.09 | 61.59% | 11 | Jan 9, 2025 | |
Anteris Technologies | Initiates Coverage On: Overweight | 22 | 5.63 | 290.76% | 1 | Jan 7, 2025 | |
Orchestra BioMed Hld... | Initiates Coverage On: Overweight | 16 | 5.26 | 204.18% | 1 | Jan 2, 2025 | |
Zimmer Biomet Holdin... | Maintains: Underweight | 125 118 | 104.65 | 12.76% | 6 | Dec 12, 2024 | |
Edwards Lifesciences | Maintains: Overweight | 85 88 | 71.02 | 23.91% | 22 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 105 109 | 85.13 | 28.04% | 15 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 19 20 | 11.08 | 80.51% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 220 234 | 267.3 | -12.46% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 58 60 | 35.79 | 67.64% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 143 149 | 113.03 | 31.82% | 24 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 402 418 | 362.71 | 15.24% | 20 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 78 86 | 95.55 | -9.99% | 12 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 85 93 | 88.01 | 5.67% | 13 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 138 113 | 79.23 | 42.62% | 5 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 490 510 | 538.11 | -5.22% | 6 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 16 | 13.49 | 18.61% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 57 61 | 47.58 | 28.21% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 17 18 | 17.23 | 4.47% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 52 54 | 30.61 | 76.41% | 15 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 158 162 | 144.67 | 11.98% | 10 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 56 58 | n/a | n/a | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 15 | n/a | n/a | 1 | Dec 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 96 | 82.68 | 16.11% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 100 | 71.25 | 40.35% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 722 418 | 210.51 | 98.57% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 31 28 | 12.74 | 119.78% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 68 67 | 18.02 | 271.81% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 11 4 | n/a | n/a | 4 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 480 | 12.84 | 3638.32% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 84 87 | 21.91 | 297.08% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 24 25 | 2.89 | 765.05% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 200 160 | n/a | n/a | 2 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 26 24 | n/a | n/a | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sell | 9 | 8.6 | 4.65% | 1 | Dec 12, 2016 |